Predictors of Successful Cardioversion with Vernakalant in Patients with Recent-Onset Atrial Fibrillation.

Forskningsoutput: TidskriftsbidragArtikel i vetenskaplig tidskrift

Abstract

Vernakalant is a novel atrial-selective antiarrhythmic drug able to convert recent-onset atrial fibrillation (AF) with reportedly low proarrhythmic risk. Successful cardioversion predictors are largely unknown. We sought to evaluate clinical and electrocardiographic predictors of cardioversion of recent-onset AF with vernakalant.

Detaljer

Författare
Enheter & grupper
Forskningsområden

Ämnesklassifikation (UKÄ) – OBLIGATORISK

  • Kardiologi
Originalspråkengelska
Sidor (från-till)140-147
TidskriftAnnals of Noninvasive Electrocardiology
Volym20
Utgåva nummer2
StatusPublished - 2015
PublikationskategoriForskning
Peer review utfördJa

Relaterad forskningsoutput

Natalia Mochalina, 2017, Lund: Lund University: Faculty of Medicine. 81 s.

Forskningsoutput: AvhandlingDoktorsavhandling (sammanläggning)

Visa alla (1)